QIAGEN Launches Comprehensive Human siRNA Library Sets
May 03 2004

QIAGEN Launches Comprehensive Human siRNA Library Sets

Venlo, The Netherlands, May 3, 2004 - QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) a leading supplier of products and technologies for nucleic acid separation, purification and handling today announced that it has launched a series of off-the-shelf human library siRNA sets, covering a broad gene family selection including kinases, GPCRs, apoptosis related genes, and oncogenes, to name a few. All siRNA designs were accomplished using the HiPerformance siRNA design algorithm that QIAGEN licensed from Novartis Pharma AG. Along with the introduction of these library siRNA sets, QIAGEN also announced the launch of Custom siRNA sets where researchers provide their targeted genes of interest and QIAGEN provide siRNA design using the same Novartis algorithm.

"Technologies in RNAi are getting more and more sophisticated, especially in siRNA design.   QIAGEN believes that HiPerformance siRNA design algorithm represents the best siRNA design tool to-date.   All siRNAs designed using this algorithm. The exceptional quality of the algorithm sets new standards in siRNA design and allows QIAGEN to offer siRNA products designed on this basis to be offered with a customer satisfaction guarantee," said Patrick Weiss, QIAGEN's Vice President of Gene Silencing and co-inventor of the TOM RNA chemistry. "With the introduction of these library siRNA sets, researchers now have an off-the-shelf, high throughput RNAi solution that covers broad gene families. Our Custom sets enable researchers to take advantage of our satisfaction guarantee on their specific gene sets. Our goal is to continue developing more siRNA sets to satisfy the growing demand for more innovative RNAi tools."

About QIAGEN in RNAi:

RNAi is a powerful discovery tool of biomedical research using siRNA segments to turn off or "silence" a specific gene to study gene expression patterns as well as the impact of specific expression profiles directly on a cell or an entire organism. QIAGEN's patented siRNA synthesis based on TOM-amidites chemistry provides highest quality and purity of RNA oligonucleotides. QIAGEN's siRNA products combined with QIAGEN's robotic platforms, RNA transfection, -purification and -amplification technologies provide fully integrated solutions for gene silencing in the most dynamic area of today's functional genomics markets.


QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).



Peer M. Schatz
Chief Executive Officer
+49 2103 29 11702
e-mail: peer.schatz@QIAGEN.com

Dr. Solveigh Mähler

Manager Investor Relations
+49 2103 29 11710
e-mail: solveigh.maehler@QIAGEN.com

Dr. Ulrich Schriek
VP Corporate Business Development
+49 2103 2911 238
e-mail: mailto:ulrich.schriek@QIAGEN.com


Share this page